| Fund ID | 805-9718979095 |
| Fund type | Private Equity Fund |
| 3(c)(1) exclusion | Yes |
| 3(c)(7) exclusion | No |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | No |
| Annual audit | Yes |
| Prepared per GAAP | No |
| Sub-advised | No |
| Sales limited to qualified investors | Yes |
| % of assets independently valued | 0% |
| Owned by the adviser or related persons | 2% |
| Owned by funds of funds | 0% |
| Owned by non-U.S. persons | 84% |
| Fund | Type | Gross assets |
|---|---|---|
| 4bio Ventures III LP | Private Equity | $154M |
| 4bio Advanced Therapies Long Equity Fund | Liquidity | $440K |
| 4bio Advanced Therapies Fund Icav | Liquidity | $440K |
4bio Ventures II LP reports $109.6 million in gross assets, among the top 41% of private funds by size.
The stated minimum investment is $5 million.
4bio Ventures II LP is managed by 4bio Partners LLP.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.